{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:44:34Z","timestamp":1792269874155,"version":"4.4.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Many of the approximately 2 million people being held in US correctional facilities are experiencing an opioid use disorder (OUD). Providing medications for OUD (MOUD) to this population is, therefore, essential to curb the opioid crisis.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the types of MOUD jails are making available, factors associated with availability, and additional supports needed for jails to address implementation challenges.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This survey study used a cross-sectional survey of jails conducted between February 2 and July 1, 2023, to explore how they administer MOUD. Publicly available county-level data were connected with the survey responses to assess how variables in the surrounding community were associated with MOUD availability. The survey was administered to jails via mail, telephone, and online survey link. Participants included jails with MOUD available that completed the survey.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Urbanization, average daily population, availability of a health care professional to administer MOUD, whether the state expanded Medicaid, average drive time to MOUD in the county, county overdose rate, and county social vulnerability were assessed.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the type of MOUD available in the jail, including buprenorphine, methadone, or naltrexone, or all 3 medications. Binary logistic regressions were conducted to identify the characteristics of jails and county-level factors associated with offering the medications.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 462 jails were invited to complete the survey based on responses to a previous nationally representative survey of jails, in which they indicated that MOUD was available to individuals in their facility. A total of 265 US jails with MOUD available were included in the analysis, representative of 1243 jails nationwide with MOUD available after weighting (812 jails [65.3%] provided buprenorphine, 646 jails [52.0%] provided naltrexone, 560 jails [45.0%] provided methadone, and 343 jails [27.6%] provided all 3 medications). Availability was associated with urbanicity, location in a Medicaid expansion state, county opioid overdose rate, and county social vulnerability. Common challenges included jail policies and procedures and the logistical accessibility of the medication.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this survey study of US jails demonstrate that jails with MOUD available still experience challenges with making all 3 types of medication available to anyone held within their facility. Policy, regulatory, financing, staffing, and educational solutions are needed to ensure that all detainees with OUD have access to treatment while incarcerated.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.5340","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:00:47Z","timestamp":1744815647000},"page":"e255340","source":"Crossref","is-referenced-by-count":10,"title":["Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails"],"prefix":"10.1001","volume":"8","author":[{"given":"Elizabeth","family":"Flanagan Balawajder","sequence":"first","affiliation":[{"name":"Public Health Department, NORC at the University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Ducharme","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Public Health Department, NORC at the University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe A.","family":"Lamuda","sequence":"additional","affiliation":[{"name":"Public Health Department, NORC at the University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marynia","family":"Kolak","sequence":"additional","affiliation":[{"name":"Department of Geography and Geographic Information Science, University of Illinois at Urbana-Champaign, Urbana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Friedmann","sequence":"additional","affiliation":[{"name":"Office of Research, Baystate Health and University of Massachusetts Chan Medical School-Baystate, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold A.","family":"Pollack","sequence":"additional","affiliation":[{"name":"Crown Family School of Social Work, Policy and Practice, University of Chicago, Chicago, Illinois"},{"name":"Department of Public Health Sciences, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Chicago, Chicago, Illinois"},{"name":"Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"issue":"1","key":"zoi250226r2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1542\/peds.2010-3710","article-title":"Cumulative prevalence of arrest from ages 8 to 23 in a national sample.","volume":"129","author":"Brame","year":"2012","journal-title":"Pediatrics"},{"key":"zoi250226r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100052","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? using multiplier approaches to estimate prevalence for an unknown population size.","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"12","key":"zoi250226r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.29676","article-title":"Comparison of rates of overdose and hospitalization after initiation of medication for opioid use disorder in the inpatient vs outpatient setting.","volume":"3","author":"Morgan","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"25","key":"zoi250226r7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: population estimates\u2014United States, 2022.","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi250226r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209103","article-title":"The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.","volume":"152","author":"Klemperer","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"1","key":"zoi250226r10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40352-023-00209-w","article-title":"Medications for opioid use disorder during incarceration and post-release outcomes.","volume":"11","author":"Cates","year":"2023","journal-title":"Health Justice"},{"issue":"13","key":"zoi250226r11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders.","volume":"374","author":"Lee","year":"2016","journal-title":"N Engl J Med"},{"key":"zoi250226r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107858","article-title":"Estimating the impact of wide scale uptake of screening and medications for opioid use disorder in US prisons and jails.","volume":"208","author":"Macmadu","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"2S","key":"zoi250226r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update.","volume":"14","author":"American Society of Addition Medicine","year":"2020","journal-title":"J Addict Med"},{"issue":"5","key":"zoi250226r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.11363","article-title":"Comparative effectiveness associated with buprenorphine and naltrexone in opioid use disorder and cooccurring polysubstance use.","volume":"5","author":"Xu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi250226r17","first-page":"20","article-title":"Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.","volume":"97","author":"Park","year":"2014","journal-title":"R I Med J (2013)"},{"issue":"3","key":"zoi250226r18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jamainternmed.2021.8114","article-title":"Opioid use disorder treatment in the age of fentanyl.","volume":"182","author":"Morris","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi250226r19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13311-019-00814-4","article-title":"Availability of medications for the treatment of alcohol and opioid use disorder in the USA.","volume":"17","author":"Abraham","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"6","key":"zoi250226r20","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s11606-022-07812-x","article-title":"Availability of medications for opioid use disorder in U.S. jails.","volume":"38","author":"Sufrin","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi250226r21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40352-022-00197-3","article-title":"Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S.","volume":"10","author":"Scott","year":"2022","journal-title":"Health Justice"},{"issue":"1","key":"zoi250226r24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40352-024-00280-x","article-title":"Facilitators and barriers to adopting or expanding medications for opioid use disorder provision in rural Colorado jails: a qualitative analysis.","volume":"12","author":"McNeely","year":"2024","journal-title":"Health Justice"},{"issue":"1","key":"zoi250226r25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13722-022-00313-6","article-title":"Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative.","volume":"17","author":"Krawczyk","year":"2022","journal-title":"Addict Sci Clin Pract"},{"issue":"9","key":"zoi250226r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.34704","article-title":"Factors associated with the availability of medications for opioid use disorder in US jails.","volume":"7","author":"Flanagan Balawajder","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"154","key":"zoi250226r29","first-page":"1","article-title":"NCHS urban-rural classification scheme for counties.","author":"Ingram","year":"2012","journal-title":"Vital Health Stat 2"},{"issue":"1","key":"zoi250226r31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science.","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implement Sci"},{"key":"zoi250226r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108746","article-title":"Uncommon and preventable: perceptions of diversion of medication for opioid use disorder in jail.","volume":"138","author":"Evans","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"zoi250226r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104252","article-title":"Diversion of medications to treat opioid use disorder: qualitative findings from formerly incarcerated adults in Massachusetts.","volume":"122","author":"Evans","year":"2023","journal-title":"Int J Drug Policy"},{"issue":"5","key":"zoi250226r35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/ADM.0000000000001180","article-title":"Correlates and patterns in use of medications to treat opioid use disorder in jail.","volume":"17","author":"Bailey","year":"2023","journal-title":"J Addict Med"},{"issue":"13","key":"zoi250226r36","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jama.2023.17700","article-title":"Medicaid expansion\u2019s final frontier: breaking state-level partisan opposition.","volume":"330","author":"O\u2019Mahen","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"zoi250226r37","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.amepre.2023.06.014","article-title":"Previous incarceration, health insurance, and the Affordable Care Act in the U.S.","volume":"65","author":"Testa","year":"2023","journal-title":"Am J Prev Med"},{"issue":"4","key":"zoi250226r38","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1377\/hlthaff.2020.01251","article-title":"Medicaid expansion increased medications for opioid use disorder among adults referred by criminal justice agencies.","volume":"40","author":"Khatri","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"zoi250226r39","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/00220426221109948","article-title":"Medication-assisted treatment in problem-solving courts: a national survey of state and local court coordinators.","volume":"53","author":"Farago","year":"2023","journal-title":"J Drug Issues"},{"issue":"4","key":"zoi250226r41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11606-023-08454-3","article-title":"Jail healthcare staffing in the US southeast: a cross-sectional survey.","volume":"39","author":"Rosen","year":"2024","journal-title":"J Gen Intern Med"},{"key":"zoi250226r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100056","article-title":"Negative attitudes about medications for opioid use disorder among criminal legal staff.","volume":"3","author":"Moore","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"2","key":"zoi250226r43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0209","article-title":"Accessibility of opioid treatment programs based on conventional vs perceived travel time measures.","volume":"7","author":"Kim","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi250226r44","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2022.115034","article-title":"Individual, interpersonal, and neighborhood measures associated with opioid use stigma: evidence from a nationally representative survey.","volume":"305","author":"Lin","year":"2022","journal-title":"Soc Sci Med"},{"key":"zoi250226r1","unstructured":"Sawyer? W, Wagner? P. Mass incarceration: the whole pie 2024. Prison Policy Initiative. March 14, 2024. Accessed August 4, 2024. https:\/\/www.prisonpolicy.org\/reports\/pie2024.html"},{"key":"zoi250226r3","unstructured":"Maruschak? LM, Minton? TD, Zeng? Z. Opioid use disorder screening and treatment in local jails, 2019. US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. April 2023. Accessed March 7, 2025. https:\/\/bjs.ojp.gov\/document\/oudstlj19.pdf"},{"key":"zoi250226r5","unstructured":"National Center for Health Statistics, National Vital Statistics System. Provisional drug overdose data. Vital Statistics Rapid Release. January 7, 2025. Accessed January 30, 2025. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi250226r8","unstructured":"Substance Abuse and Mental Health Services Administration. Introduction to medications for opioid use disorder treatment. Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families. 2018. Accessed May 12, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535270\/"},{"key":"zoi250226r13","unstructured":"American Society of Addiction Medicine. Public policy statement on treatment of opioid use disorder in correctional settings. Published July 15, 2020. Revised January 23, 2025. Accessed March 7, 2025. https:\/\/www.asam.org\/advocacy\/public-policy-statements\/details\/public-policy-statements\/2025\/01\/24\/treatment-of-opioid-use-disorder-in-correctional-settings"},{"key":"zoi250226r14","unstructured":"New York State Office of Addiction Services and Supports. Medications for the treatment of opioid use disorder. Accessed January 17, 2025. https:\/\/oasas.ny.gov\/providers\/medications-treatment-opioid-use-disorder"},{"key":"zoi250226r22","unstructured":"The White House. White House Drug Policy Director statement on historic new action to support reentry and addiction treatment access in carceral settings. July 2, 2024. Accessed August 4, 2024. https:\/\/bidenwhitehouse.archives.gov\/ondcp\/briefing-room\/2024\/07\/02\/white-house-drug-policy-director-statement-on-historic-new-action-to-support-reentry-and-addiction-treatment-access-in-carceral-settings\/#:~:text=Under%20this%20important%20action%20today,with%20the%20tools%20and%20resources"},{"key":"zoi250226r23","unstructured":"Centers for Medicare & Medicaid Services. HHS releases new guidance to encourage states to apply for new Medicaid reentry section 1115 demonstration opportunity to increase health care for people leaving carceral facilities. April 17, 2023. Accessed March 28, 2024. https:\/\/www.cms.gov\/newsroom\/press-releases\/hhs-releases-new-guidance-encourage-states-apply-new-medicaid-reentry-section-1115-demonstration"},{"key":"zoi250226r26","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). 42 CFR Part 8 Final Rule. January 31, 2024. Accessed October 4, 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines\/42-cfr-part-8"},{"key":"zoi250226r28","unstructured":"University of Illinois at Urbana-Champaign. Opioid Environment Policy Scan (OEPS) Data Warehouse. OEPS Explorer Data Download. January 21, 2022. Accessed March 28, 2024. https:\/\/oeps.healthyregions.org\/"},{"key":"zoi250226r30","unstructured":"Centers for Disease Control and Prevention. Agency for Toxic Substances and Disease Registry. Geospatial Research, Analysis, and Services Program. CDC\/ATSDR Social Vulnerability Index 2020. Accessed January 4, 2024. https:\/\/www.atsdr.cdc.gov\/place-health\/php\/svi\/svi-data-documentation-download.html?CDC_AAref_Val=https:\/\/www.atsdr.cdc.gov\/placeandhealth\/svi\/data_documentation_download.html"},{"key":"zoi250226r32","unstructured":"National Sheriff\u2019s Association, National Commission on Correctional Health Care. Jail-based medication-assisted treatment: promising practices, guidelines, and resources for the field. October 2018. Accessed January 9, 2024. https:\/\/www.ncchc.org\/wp-content\/uploads\/Jail-Based-MAT-PPG-web.pdf"},{"key":"zoi250226r40","unstructured":"118th US Congress. Consolidated Appropriations Act of 2024. Vol 25. March 9, 2024. Accessed March 7, 2025. https:\/\/www.congress.gov\/118\/plaws\/publ42\/PLAW-118publ42.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2832851\/flanagan_balawajder_2025_oi_250226_1744215535.34676.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:00:53Z","timestamp":1744815653000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2832851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.5340","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]}}}